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Magnetic resonance imagingAim: To evaluate the ability of DWIs to distinguish between benign and malignant focal
hepatic lesions (FHLs) using 3 T MR.
Material and methods: A total of 73 FHLs in 48 patients were evaluated. There were 28
benign lesions including 13 hemangiomas (17.8%), 8 hepatic cysts (10.9%), 4 regenerating
hepatic nodules (5.4%), 2 adenomas (2.7%) and 1 focal fatty infiltration (1.3%). The others 45
lesions were malignant including 28 hepatocellular carcinomas (38.3%), 15 metastases
(20.5%) and 2 cholangiocarcinomas (2.7%). The study used two b values (0 and
800 s/mm2) and the ADC values were calculated.
Results: The mean ADC value for simple liver cysts was 2.58 ± 0.35  103 mm2/s, for solid
benign lesions was 1.63 ± 0.41  103 mm2/s and for malignant lesions was
1.21 ± 0.38  103 mm2/s with statistical difference (p < 0.0001). We found that the best
ADC cutoff value was 1.49  103 mm2/s with accuracy of 83.6% in differentiation between
the all benign and malignant FHLs. While with exclusion of the cystic hepatic lesions, the
best ADC cutoff value was reduced to be 1.35  103 mm2/s with accuracy of 78.5%.
Conclusions: DWI can be used to differentiate between the benign and malignant FHLs.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Confident diagnosis of the focal hepatic lesions (FHLs) is
so essential for proper management. Many benign and
malignant FHLs have typical radiological features. In clini-
cal practice, improvement in different radiological modali-
ties during the last three decades, particularly the
multislice computed tomography (MSCT) and magnetic
resonance imaging (MRI) have succeeded to solve and
diagnose many indeterminate FHLs with no need of
histopathological correlation [1–4]. Recently, the role ofMRI and Positron emission tomography-computerized
tomography (PET-CT) has proven to have high capability
to differentiate between benign and malignant FHLs. Yet
some hepatic lesions are still indeterminate with atypical
features in spite of the progress in these different imaging
modalities.
Diffusion weighted imaging (DWI) is very useful for
assessment of FHLs with high tissue contrast and no need
to expose the patient to ionizing radiation [5]. The dynamic
contrast enhanced and post contrast subtraction MR
images during the different phases of contrast injection
are so helpful to diagnose the FHLs and determine the post
interventional tumor viability as well [6].
Since the 1990s, DWI using single-shot echo-planar
imaging was successfully used in the neuro-radiology, par-
ticularly in early detection of cerebral ischemic insult [7,8].
Later on, with progress in theMRI techniques, development
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channel coils, DWI expands its clinical role in oncology.
Regarding the liver imaging, many studies have proved that
DWI is capable to detect and characterize benign and
malignant FHLs [9–11]. In the last two decades, many stud-
ies were performed concerned with the assessment and
validity of DWI in the characterization and detection of
FHLs [12–21].
The DWI is based on the measurement of movement
and diffusion of the water molecule protons within the
imaged soft tissue, within the intra- and extracellular com-
partments. The DWI depends on the cell membrane integ-
rity and lipophilicity in addition to cellularity within the
lesion [22,23]. If the water protons moves freely within
the tissues of low cellularity, that will represent facilitated
diffusion. While if the movement of the water protons is
restricted due to high cellularity of the tissue that will rep-
resent restricted diffusion. Therefore, DWIs can be ana-
lyzed in two ways, qualitatively, by visual assessment of
signal intensity, and quantitatively, by measurement of
the apparent diffusion coefficient (ADC). ADC values are
calculated from the slope of the line drawn between the
y-axis (logarithm of signal decay) and x-axis (different b
values) [24]. ADC values are considered the magnitude of
water diffusion, and these values are generated and calcu-
lated in automatic way using special software. These val-
ues are displayed in ADC maps.
Benign and malignant focal lesions have different ADC
values, and malignant tumors have a high cellularity and
low extracellular space volume, so resulting in impeded
water proton diffusion and therefore low ADC values. In
contrast, benign lesions are characterized by an increased
amount of extracellular matrix with minimal increase in
cellular density, resulting in higher ADCs [22,23].
In spite of the large number of studies were performed
in liver imaging using DWI, the ADC cutoff values in the
differentiation between the benign and malignant hepatic
lesions remain unclear and sometime confusing. Most of
the previous studies used MR 1.0 or 1.5 T and include hep-
atic cysts. Our study used 3.0 T MR scanner. The aim of our
study was to evaluate the ability of ADC to distinguish
between benign and malignant hepatic lesions with and
without inclusion of the cystic hepatic lesions.2. Patients and methods
2.1. Patients
After approval of the institutional review board, this
prospective study was done on 48 patients with 73 lesions
over a period of 9 months between September 2014 and
May 2015. Those patients were referred from the different
medical and surgical departments of Cairo University
Hospital. Informed consent was obtained from all patients
after full explanation of the benefits and risks of the
procedure.
2.1.1. Inclusion and exclusion criteria
2.1.1.1. Inclusion criteria.
(1) Adult patients over the age of 20 years.(2) The presence of at least one FHL detected by conven-
tional MR, U/S or CT examination and measuring at
least 1 cm in maximum diameter.2.1.1.2. Exclusion criteria.
(1) Patients who had no FHL or had lesion less than 1 cm
in diameter.
(2) Patients treated by radiofrequency or chemoem-
bolization.
(3) Patients with contraindications for MR imaging;
claustrophobia, pacemaker or metal implants.
(4) Patients with contraindication for contrast material
including known allergy and renal insufficiency
(glomerular filtration rate <30 mL/min/1.73 m2).
2.2. Liver MRI imaging protocol
MRI studies were performed on Philips Achieva, Nether-
land 3.0 T MR unit by using body phased-array coil with
patient in supine position. The examinations were per-
formed by professional operator (more than 5 years expe-
rience). The MR sequences were performed in order as
follows:
1. Unenhanced axial T1-Fast Field Echo (T1-FFE) images.
Parameters are repetition time (TR) 2.3/ms, echo time
(TE) 10 ms, number of signal averages (NSA) = 2, thick-
ness = 9 mm, gap = 1.5 and matrix 268  180.
2. Axial T2-Fast Field Echo (T2-FFE) images. Parameters
are repetition time (TR) 750–1000/ms, echo time (TE)
> 100 ms, number of signal averages (NSA) = 2, thick-
ness = 9 mm, gap = 1.5 and matrix 308  218.
3. 3D T1-weighted isotropic imaging (THRIVE): before
contrast injection, parameters are TR 3.3/ms, TE
1.6 ms and flip angle of 10.
4. Diffusion weighted sequences (Respiratory-triggered
protocol using b values = 0 and 800 s/mm2). Diffusion-
weighted MR sequences were performed with the
single shot echo-planar imaging (EPI) technique.
Subsequent measurement of mean apparent diffusion
coefficient (ADC) value was done for each FHL.
5. Axial 3D dynamic contrast material enhanced
(Gd-DTPA) imaging (Axial 3D T1-weighted isotropic
imaging/THRIVE images) was done. Bolus of contrast
injection (0.2 mL/kg body weight of Gd-DTPA) was per-
formed followed by flush with 25 ml of sterile 0.9%
saline solution. The arterial, portal and delayed phases
were scanned at 20 s, 60 s and 5 min after contrast
injection respectively. Subtraction images for the
arterial and portal phases were performed for all cases.
2.3. Lesion characterization
For benign lesions (hepatic cysts and cavernous heman-
giomas) of typical MRI findings, no histopathological con-
firmation was done, just follow-up with triphasic CT or
MR within 6–8 months. The diagnosis of hepatic adenomas
was confirmed by their stable typical pattern of contrast
enhancement and morphological features on the previous
and follow-up studies (within 1–2 years duration).
Table 1
Pathological classification of the hepatic focal lesions in the present study.
Lesion Number Percentage (%)
Hepatocellular carcinoma (HCC) 28 38.3
Metastasis 15 20.5
Cholangiocarcinoma 2 2.7
Hemangioma 13 17.8
Hepatic cyst 8 10.9
Regeneration nodules 4 5.4
Adenoma 2 2.7
Focal fatty infiltration 1 1.3
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were diagnosed by typicalmalignant contrast enhancement
criteria (early contrast uptake in the arterial phase and
washout in the delayed phase, best appreciated at the post
contrast subtraction MR images) together with their malig-
nant behavior (size progression in follow-up CT orMR stud-
ies, invasion of portal vein or IVC). Three lesions of HCC
within the aforementioned cases were proved to be
hyper-metabolic in PET-CT as well. Other lesions of HCC
lacked their typical pathological contrast enhancement
and malignant behavior, and these lesions were confirmed
as hypovascular HCC by biopsy and histopathological corre-
lation. All metastatic lesions had known extra hepatic pri-
mary tumor. For characterization of the all metastatic
hepatic lesions, correlation with the previous CT, PET-CT
or MR examinations was performed. All metastatic cases
were confirmed by changing their morphological features
(either post therapeutic regression or progression) in short
term follow-up within 3–6 months with exceptional few
metastatic lesions needed histopathological confirmation.
For undetermined and atypical lesions, CT or ultrasound
guided biopsies were performed and histopathological ver-
ification was within a time frame of 3 months after MRI
examination. For ethical consideration, patientswithmulti-
ple FHLs, we got biopsy and histopathological confirmation
fromonly one of themultiple lesions, notmore. Histopatho-
logical confirmations were done in 9 patients, and some of
them had multiple lesions (2 cholangiocarcinomas, 6
metastases and 9 HCCs).
2.4. Statistical analysis
Data were analyzed by two radiology consultants (more
than 10 years experience) using statistical software R ver-
sion 3.1.2 with p < 0.001. The ADC values were calculated
using circular region of interest (ROI) for each FHL at the
ADC map. Mean ADC value for each lesion was expressed.
For lesions between 1 and 3 cm in maximum diameters,
mean ADC value was calculated from one circle of ROI
within the center of the lesion. For large lesions, two to
four circular ROIs were drawn manually and the mean
ADC reading for all circles was calculated. In case of large
necrotic lesions, circles of ROI were calculated within the
peripheral solid soft tissue components. Quantitative data
of the three groups (simple liver cysts, benign solid and
malignant lesions) were expressed as mean ADC
value ± standard deviation (SD) for each group collectively.
3. Results
3.1. Patients
73 FHLs were detected and diagnosed in 48 patients
who fulfilled the inclusion criteria. Mean age of these
patients was 51 years (52% of patients between 40 and
60 years) with 29 males (60%) and 19 females (40%).
3.2. Liver lesions
There were 28 benign lesions (Table 1) including 13
hemangiomas (17.8%), 8 hepatic cysts (10.9%), 4 regenerat-ing hepatic nodules (5.4%), 2 adenomas (2.7%) and 1 focal
fatty infiltration (1.3%). The other 45 lesions were malig-
nant (Table 1) including 28 hepatocellular carcinomas
(38.3%), 15 metastases (20.5%) and 2 cholangiocarcinomas
(2.7%). The metastatic lesions were composed of 10 solid
lesions and 5 cystic lesions.
3.3. Qualitative assessment on DW imaging
The simple hepatic cysts and hemangiomas showed
high signal in DWIs and ADCmap (T2 shine through effect),
denoting facilitated diffusion (Fig. 1). The other benign
lesions (adenomas, focal fatty infiltration and regeneration
nodules) showed near signal intensity to the surrounding
liver parenchyma in ADC map with no significant diffusion
restriction.
On contrast, the solid malignant lesions (HCC, metasta-
sis and cholangiocarcinoma) showed significant diffusion
restriction evident by high signal in DWIs with corre-
sponding low signal in ADC map (Figs. 2–5).
3.4. Quantitative (ADC) evaluation
Benign lesions showed high ADC values, more pro-
nounced at the hepatic cysts and hemangiomas, while
the malignant lesions showed low ADC values, more pro-
nounced in cholangiocarcinomas and HCCs.
The mean ADC value for simple liver cysts was
2.58 ± 0.35  103 mm2/s (CI: 2.29–2.87), for solid benign
lesions was 1.63 ± 0.41  103 mm2/s (CI: 1.44–1.82) and
for malignant lesions was 1.21 ± 0.38  103 mm2/s (CI:
1.09–1.32). The difference between the mean ADC values
of benign and malignant lesions was statistically signifi-
cant (P < 0.001) (Table 2).
Regarding the differentiation between the all benign
and malignant FHLs including the cystic lesions, we found
that the best ADC cutoff value was 1.49  103 mm2/s with
accuracy of 83.6% (Fig. 6). On the other hand with exclu-
sion of the cystic hepatic lesions, the best cutoff to differ-
entiate between the solid benign and malignant hepatic
lesions was reduced to be 1.35  103 mm2/s, with accu-
racy of 78.5% (Fig. 7).4. Discussion
Early detection and proper characterization of the FHLs
are challenging for the radiologists and researchers, partic-
ularly at the endemic countries where liver cirrhosis and
Fig. 1. 50-Year-old female patient with two hemangiomas. (a–f) Arterial, portal and delayed phases show two focal lesions at the right and left hepatic
lobes with centripetal contrast enhancement pattern (iris sign). (g and h) DWIs at b800, the lesions show high signal intensity in DWIs and corresponding
high ADC values (T2 shine through effect). (i and j) ADC values: 1.8  103 mm2/s and 1.9  103 mm2/s.
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Fig. 2. 65-Year-old male patient with multicentric hepatocellular carcinoma. (a and b) Axial T1WIs, multiple lesions of heterogeneous signal intensity, the
largest at the left hepatic lobe shows exophytic component. (c and d) DWIs at b800, the lesions show restricted diffusion. (e and f) ADC values:
1.0  103 mm2/s and 0.9  103 mm2/s at the largest two lesions (low ADC values).
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ades, the progress in the MR scanners and fast imaging
MR techniques enabled proper characterization of the
FHLs. However, many FHLs are still indeterminate; for
example, sometimes vascular metastasis can be confused
with hemangiomas during imaging [25]. Many studies
have been published regarding the role of DWI in charac-
terization of the FHLs [5,12,26–28].
In the other side, DWI plays an important role not only
in the characterization but also in detection of the FHLs,
particularly the liver metastases [29]. DWI proved to have
high ability to detect FHLs as compared to the fat-
suppressed fast spin echo and respiratory-triggered T2weighted sequences [16,20,30]. In addition, the detection
of small FHLs can be increased by using respiratory-
triggered diffusion sequences because of high spatial reso-
lution and an adequate signal-to-noise ratio (SNR) [21,31].
In recent meta-analysis study published by Chen et al. it
was found that breath-hold MR diffusion imaging had high
diagnostic capability for differentiation between benign
and malignant FHLs [32]. Thus DWI can be widely used
with or without capability of respiratory triggering in MR
scanners. DWI using low b values (50–150 s/mm2) is
reported to be useful in detection of FHLs while DWI using
high b values (500–1000 s/mm2) is reported to be greater
in characterization of FHLs. Therefore DWI should be
Fig. 3. 66-Year-old male patent with pathologically proved cholangiocarcinoma. (a and b) Axial portal phase, large infiltrative mass lesion of heterogeneous
enhancement is seen involving the caudate and left hepatic lobe and other small neoplastic satellite nodules at the right hepatic lobe. (c and d) DWIs at
b800, the lesions show restricted diffusion. (e and f) ADC values: 1.1  103 mm2/s at the largest mass lesion (low ADC values).
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work. Most authors utilized b values in the range of 500–
800  103 mm2/s for the evaluation of FHLs [33,34].
The ADC value is the measure of the tissue cellularity
and thus it is considered as indicator of malignancy. The
malignant FHLs proved to have low ADC values as com-
pared to benign FHLs [35], regardless of the different tech-
nical parameters and the MR equipment. There are also
some overlaps in the ADC values between the benign and
malignant FHLs. There is inverse relationship between
the ADC and b values (by increasing the b values used,
the ADC values decreasing).
Despite different techniques in DWI, on a review paper
of Taouli and Koh [36], the reported ADC values for
different FHLs are nearly similar between different studies
and around 0.9–1.26  103 mm2/s for malignant lesions,
over 1.56  103 mm2/s for benign lesions and over2.56  103 mm2/s for cysts. In addition, all reported
studies included cysts when calculating the accuracy for
the differentiation of benign and malignant lesions and
with similar ADC cutoff values, ranging from 1.4 to
1.66  103 mm2/s, and they reached sensitivities of
74–100% and specificity of 77–100%.
Bruegel et al. [35] found that the ADC value of
1.63  103 mm2/s could be used in 88% of the FHLs as cut-
off to accurately differentiate between the benign or malig-
nant lesions (including the cystic hepatic lesions).
In other previous study performed by Testa et al. [37],
with inclusion of the cystic hepatic lesions, the ADC value
of 1.56  103 mm2/s could be used as a cutoff in differen-
tiation between metastatic from benign liver lesions, with
an accuracy of 78%. With exclusion of the cystic hepatic
lesions, the ADC cutoff value and its accuracy were reduced
to be 1.26  103 mm2/s and 71% respectively.
Fig. 4. 45-Year-old female patent with left hepatic lobe metastatic lesion of thyroid carcinoma. Partial right lobectomy was previously performed for other
metastatic lesion. (a and b) Axial subtraction arterial and portal phases, hypervascular metastatic lesion at the left hepatic lobe. (c) DWIs at b800, the lesion
shows restricted diffusion. (d) ADC values: 1.2  103 mm2/s (low ADC values).
Fig. 5. 52-Year-old male patent with multiple hepatic metastatic lesions of colonic carcinoma. (a) Axial portal phase, multiple (three) hypovascular hepatic
metastatic lesions. (b) DWIs at b800, the lesions show restricted diffusion. (c) ADC values: 1.05  103 mm2/s, 1.01  103 mm2/s and 1.27  103 mm2/s
(low ADC values).
Table 2
ADC values of the hepatic focal lesions (n = 73) in the studies 48 patients.
SD (standard deviation), SEM (standard error of the mean), CI (confidence
interval).
Lesion N Mean ± SD SEM 95% CI P value
Malignant 45 1.21 ± 0.38 0.06 1.09–1.32 <0.001
Benign solid 20 1.63 ± 0.41 0.09 1.44–1.82
Cysts 8 2.58 ± 0.35 0.12 2.29–2.87
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increased in the last decade, because of its advantages over
1.5 T. The increase in overall SNR one of the major
advantages of the 3.0 T MR that results in increased spatialresolution, increased temporal resolution, or a combina-
tion of the two. The increase in the spatial resolution,
results in improvement and high definition for areas of
restricted diffusion. On the other hand the increased tem-
poral resolution results in reduction in the acquisition time
particularly at the volumetric scans, post contrast dynamic
series and subtraction processing. The combination of
increased spatial and temporal resolution results in higher
contrast to noise ratio and reduction of the required dose
of gadolinium at 3.0 T [38,39].
Most of the prior studies used 1.0 and 1.5 T MR scanners
and included cystic lesions within the examined FHLs
[15,16,40,41]. The simple cysts have very high ADC values
AUC 95% CI Cut-oﬀ Sensivity Speciﬁcity PPV NPV Accuracy
0.848 0.747-0.949 1.49 86.7% 78.6% 86.7% 78.6% 83.6%
Fig. 6. ROC analysis to differentiate all malignant from benign lesions. ADC cutoff value for differentiation between the all benign and malignant hepatic
focal lesions. AUC (area under the curve), PPV (positive predictive values), NPV (negative predictive values).
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the simple hepatic cysts in these studies resulted in
increasing the mean ADC values of the benign lesions,
and subsequently the ADC cutoff value between the benign
and malignant FHLs were increased, leading to selection
bias [15,35,42]. The simple hepatic cysts are easily diag-
nosed in most cases with no need to MRI examination.
The most challenging task is to differentiate between the
solid benign and malignant lesions, particularly the hepatic
deposits.
Therefore, the authors in the present study used 3.0 T
MR scanner to get its technical benefits and analyze the
results with and without inclusion of the cystic hepatic
lesions. b values 0–800 s/mm2 were utilized. The mean
ADC values obtained for the malignant, benign and simple
cystic FHLs were 1.21 ± 0.38  103 mm2/s, 1.63 ± 0.41 
103 mm2/s and 2.58 ± 0.35  103 mm2/s respectively
and these results are in the same range as those previously
reported [42]. With inclusion of the cystic hepatic lesions,
ADC cutoff value of 1.49  103 mm2/s can be used to dis-
tinguish the malignant from the benign FHLs with a sensi-
tivity of 87%, a specificity of 79% and an overall accuracy of84%. With exclusion of the simple cysts from the benign
hepatic lesions and the cystic metastatic lesions from the
malignant lesions, the ADC cutoff value is dropped into
1.35  103 mm2/s with sensitivity of 76%, a specificity of
85% and an overall accuracy of 79%. The little difference
in the ADC cutoff values that presented in our study and
other published articles can be mainly explained by differ-
ent physical parameters including field strength of the MR
magnet, b values used, breath-hold or respiratory triggered
diffusion imaging. There is also some overlaps in the ADC
values between the benign and malignant FHLs.
Few reports were published regarding the comparison
between the MR scanners with different field strengths in
abdominal applications. Dale et al. reported significant dif-
ference in ADC value of normal hepatic parenchyma
between 1.5 and 3.0 T MR scanners [43]. In the same man-
ner, the expected ADC value of the same FHL can be chan-
ged between the MR scanners of different field strengths.
By growing the availability and abdominal applications of
3.0 T MR scanner worldwide, the significance of DWI and
calculation of ADC values in characterization of FHLs
becomes so important. Thus many studies will be needed
AUC 95% CI Cut-oﬀ Sensivity Speciﬁcity PPV NPV Accuracy
0.793 0.662-0.924 1.35 75.6% 85.0% 69.2% 91.9% 78.5%
Fig. 7. ROC analysis to differentiate malignant from benign lesions not including simple cysts and cystic metastatic lesions. ADC cutoff value for
differentiation between the solid benign and malignant hepatic focal lesions.
M. Talaat Ali et al. / The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1231–1241 1239to verify this issue and get benefit of its higher image qual-
ity in short acquisition time. Our study is considered one of
the earliest studies using 3.0 T MR scanner.
In contrast, Agnello et al. reported that the differentia-
tion between solid benign and malignant lesions using
DWIs and ADC values can be indistinguishable [44]. They
found that some benign solid lesions showed diffusion
restriction. Sandrasegaran et al. found that the DWI and
ADC calculation played minimal role in differentiation
and characterization of FHLs [45]. In addition Parikh et al.
concluded there was no difference regarding the ADC val-
ues between the liver deposits and the benign hepatic
lesions [20]. Taouli et al. concluded that there was no sig-
nificant difference in the ADC values between the normal
hepatic parenchyma and the benign FHLs [46].
The differentiation between the benign and the malig-
nant hepatic cystic lesions (including cystic metastasis or
highly necrotic HCC) is another challenge, and only ADC
calculations may be misleading (Fig. 8). The differentiation
is mainly based on their morphological features onconventional MR sequences, follow-up results and clinical
data. Therefore, DWIs should not be interpreted alone
but in conjunction with the lesion signal detected at the
conventional MR sequences and its behavior at the
dynamic post contrast series, to be more effective and suc-
cessful to reach the proper diagnosis.4.1. Limitations
There were some limitations of our work. First, no
histopathological confirmations were done for the benign
and some malignant hepatic lesions. The diagnosis of these
lesions was based on their typical findings in the different
imaging tools and their behavior on serial MRI examina-
tions. Second, we had small number of cases with cholan-
giocarcinoma, adenomas and other benign solid liver
masses. Third, we used only two different b values (0 and
800 s/mm2), not more in characterization of the FHLs. Fur-
ther studies using 3.0 T MR scanner especially for the solid
Fig. 8. 44-Year-old male patient with right hepatic lobe cystic metastatic lesion of gastrointestinal stromal tumor (GIST). (a–c) Arterial, portal and delayed
phases show right hepatic lobe cystic focal lesion with progressive marginal irregular contrast enhancement pattern. (d) T2WIs, the lesion shows high signal
intensity. (e) DWIs at b800, the lesion shows facilitated diffusion. (f) ADC value: 2.2  103 mm2/s (high ADC value).
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for better judgment.5. Conclusion
In conclusion, DWIs can be used in conjunction with
conventional imaging tools to differentiate between the
majority of the benign and malignant FHLs. In addition,
when contrast administration is contraindicated, DWIs
and calculation of ADC values can be a good substitute
for contrast enhanced MR sequences. With the exclusion
of hepatic cysts, ADC cutoff value obtained in the study
should be utilized.References
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